weeks. The serum level of elastase remained unchanged. The administration of lactoferrin in the chronic phase of adjuvant arthritis resulted in a steady suppression of the inflammatory process (decreased hind paws swelling and local temperature, white blood cell count and erythrocyte sedimentation rate, an increase in weight gaining and a decrease in serum elastase level), which lasted until the end of experiment (day 50). This effect was achieved with lower doses of the drug (9 mg/kg), though its strength was dose-dependent. The maximal suppression of adjuvant arthritis was obtained with the repeated injections of lactoferrin (5 injections every other day with total dose of 60 mg/kg) in the chronic phase of adjuvant arthritis (days 23-31). In these rats the serum concentration of elastase was reduced down to normal level and the rate of generalisation was less than 8%. Conclusion Lactoferrin is a potent anti-inflammatory agent effective in treatment of adjuvant arthritis in rats. The maximal suppression of the inflammatory process is obtained in the chronic phase of adjuvant arthritis.

No abstract

Conclusion UGI hospitalisation rates were 2-4x lower, and less UGI-related healthcare resources were utilised for celecoxib-vs NSAID-treated patients. The incidence of serious clinical UGI safety endpoints was significantly lower in the celecoxib-treated patients. Sponsored by Pharmacia Corporation and Pfizer, Inc.

= 3482) vs. rofecoxib (n = 6290); and, 1.31 (0.86, 2.01) when comparing non-naproxen NSAIDs or placebo (n = 6017) vs. rofecoxib (n = 7675). Conclusion (1) The risk of sustaining a thrombotic cardiovascular event was similar in patients treated with rofecoxib, placebo, or non-selective NSAIDs without sustained effects on platelet function and, (2) the risk of sustaining a thrombotic cardiovascular event was reduced in patients treated with naproxen compared to rofecoxib. This reduction in events on naproxen is likely due to its ability to maintain near complete inhibition of platelet function throughout its dosing interval.

No abstract